Landmark Mariano Barbacid Therapy Achieves Total Tumor Regression
- Feb 10
- 2 min read

A research team led by renowned biochemist Mariano Barbacid at Spain’s National Cancer Research Centre (CNIO) has reported a significant medical milestone: a newly designed triple-drug therapy that completely eliminated aggressive pancreatic tumours in laboratory mice. The study, published in the Proceedings of the National Academy of Sciences (PNAS), found that the treatment resulted in total tumour regression with no relapse or significant side effects in the test subjects.
Pancreatic ductal adenocarcinoma is historically resistant to treatment because it adapts and bypasses single-target drugs. Barbacid’s approach uses a "triple therapy" to shut down multiple survival mechanisms simultaneously, specifically targeting the KRAS protein—a genetic switch present in 90% of pancreatic cancers. While independent experts have called the results "groundbreaking" and "compelling," they have also raised concerns regarding how the news was communicated to the public.
The announcement triggered a wave of both hope and controversy. Following a series of high-profile media appearances, including a segment on the Spanish television show El Hormiguero where the results were hailed as a "miracle," the CNIO was flooded with messages from desperate patients. However, the scientific community has urged caution, noting that while 45 mice were "cured," approximately 90% of therapies that succeed in mice fail during human clinical trials.
Further scrutiny has focused on potential conflicts of interest. Barbacid and his colleagues recently founded Vega Oncotargets to commercially develop these therapies. While the researchers are currently seeking €30 million to transition to human trials, experts emphasize that a confirmed cure for humans remains years away. For now, the scientific world remains "cautiously optimistic," viewing this as a vital step toward making one of the world's deadliest cancers finally vulnerable to targeted treatment.
🔖 Sources
Keywords: Mariano Barbacid Therapy










Comments